<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-four (44) patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> received identical combination chemotherapy on the basis of body surface area </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo>, more common in those with <z:e sem="disease" ids="C0000735" disease_type="Neoplastic Process" abbrv="">abdominal tumours</z:e>, were at significantly greater risk of developing severe <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> (less than 1000 cells/dl) than those with <z:mpath ids='MPATH_458'>normal</z:mpath> renal function (P less than 0.0001) </plain></SENT>
<SENT sid="2" pm="."><plain>Similar results were seen in a series of 8 patients with <z:mpath ids='MPATH_458'>normal</z:mpath> marrows treated with only i.v. <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Giving a lower initial dose of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> seemed to reduce the risk of severe <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> in 5 additional patients with evidence of <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The mechanism is postulated as delayed excretion of the active metabolites of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Adjustment of the chemotherapeutic dose should be considered when treating patients with <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> </plain></SENT>
</text></document>